NLS Pharmaceutics Unveils New Share Purchase Warrant NLS Pharmaceutics (NLSP) has released an update. NLS Pharmaceutics Ltd. has announced the issuance of a new Common Share Purchase Warrant, which al…
NLS Pharmaceutics looks to raise $0.79M via securities offering NLS Pharmaceutics (NLSP) said Friday it will undertake a registered direct offering to raise $0.79 million. NLSP is -13.4% to $0.21 The company said it has entered into a definitive agreeme
NLS Pharmaceutics’ Breakthrough in Parkinson’s Research NLS Pharmaceutics (NLSP) has released an update. NLS Pharmaceutics Ltd. has announced promising preclinical results for its novel Parkinson’s Disea…
NLS Pharmaceutics Receives Nasdaq Compliance Extension NLS Pharmaceutics (NLSP) has released an update. NLS Pharmaceutics Ltd., a Swiss biopharmaceutical company, has been granted an extension by the Na…
Nasdaq Panel Grants NLS Pharmaceutics' Request for Extension to Comply with Continued Listing Requirements ZURICH, SWITZERLAND / ACCESSWIRE / June 25, 2024 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a leading Swiss biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, announced today that it received notice from the Nasdaq Hearings Panel ("Panel") of The Nasdaq Stock Market ("Nasdaq") that it has granted the Company an extension to regain compliance with the continued listing requirements for The Nasdaq Capital Market, as discussed more fully below.
PLTR Stock: Palantir Bags New Partnership With ARPA-H for AI/ML Palantir (NYSE: PLTR ) stock is in the news Thursday after the big data and artificial intelligence ( AI ) analytics company announced a new partnership with the Advanced Research Projects Agency for Health (ARPA-H). The partnership has the two companies teaming up on AI and machine learning ( ML ). This will see Palantir assist ARPA-H with its mission goal of accelerating better health outcomes. That includes high-potential, high-impact biomedical and health research not possible through traditional research or commercial activity. Palantir will provide ARPA-H with its AIP and Foundry software to help it with key workflows. That includes data infrastructure for its core operations. It’s a two-year contract for Palantir that is worth $19 million. What This Means for PLTR Stock Palantir head of health and senior vice president of Federal said the following about the partnership. “ARPA-H is an incredible investment in the next generation of life-changing healthcare outcomes. We are honored to provide our software to support their mission and deliver the latest commercial technology to transform their operations.” PLTR stock is up 2.2% as of Thursday morning.
Why Is NLS Pharmaceutics (NLSP) Stock Down 23% Today? NLS Pharmaceutics (NASDAQ: NLSP ) stock is down on Thursday but that's only after the clinical-stage biopharmaceutical company's shares underwent a massive rally on Tuesday. Shares of NLSP stock closed out Tuesday, the prior day of trading due to the Juneteenth holiday on Wednesday, up 82.1%.
Why Is NLS Pharmaceutics (NLSP) Stock Up 163% Today? NLS Pharmaceutics (NASDAQ: NLSP ) stock is rocketing higher on Tuesday alongside heavy pre-market trading of the clinical-stage biopharmaceutical company's shares. This has more than 73 million shares of the stock changing hands as of this writing.
NLS Pharmaceutics Unveils Innovative Narcolepsy Treatment NLS Pharmaceutics (NLSP) has released an update. NLS Pharmaceutics has announced a groundbreaking patent application for a new series of Dual Non-S…
NLS Pharmaceutics Calls Shareholders’ Meeting NLS Pharmaceutics (NLSP) has released an update. NLS Pharmaceutics Ltd. has announced an ordinary shareholders’ meeting scheduled for June 27, 2024…